Research programme: ICP4 antagonists - Signal

Drug Profile

Research programme: ICP4 antagonists - Signal

Alternative Names: ICP4 antagonists research programme - Signal

Latest Information Update: 07 Nov 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Signal Research Division
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 07 Nov 2003 Discontinued - Preclinical for Herpes simplex virus infections in USA (unspecified route)
  • 27 Aug 2001 No-Development-Reported for Herpes simplex virus infections in USA (Unknown route)
  • 07 Sep 2000 Signal Pharmaceuticals has been acquired by Celgene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top